NCT05779657View on ClinicalTrials.gov

Combined Ketamine and Midazolam for Generalized Convulsive Status Epilepticus

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

144

Participants

Timeline

Start Date

March 21, 2023

Primary Completion Date

August 26, 2024

Study Completion Date

August 30, 2024

Conditions
Generalized Convulsive Status Epilepticus
Interventions
DRUG

Ketamine

Intravenous ketamine 2 mg/kg (max 60 mg) over 2 minutes (diluted with isotonic saline to 5 mg/ml concentration)

DRUG

Midazolam

Intravenous midazolam 0.2 mg/kg (maximum 10 mg) over 2 minutes

DRUG

Placebo

Intravenous isotonic saline 0.4 ml/kg (max 12 ml) over 5 minutes

Trial Locations (1)

82524

Sohag University Hospital, Sohag

All Listed Sponsors
lead

Sohag University

OTHER